Media stories about Dynavax Technologies Corporation (NASDAQ:DVAX) have trended very positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dynavax Technologies Corporation earned a daily sentiment score of 0.69 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media headlines that may have impacted Accern’s analysis:

Dynavax Technologies Corporation (NASDAQ DVAX) traded down 2.65% during mid-day trading on Friday, reaching $16.55. The company’s stock had a trading volume of 5,967,700 shares. The firm’s 50 day moving average price is $9.75 and its 200 day moving average price is $6.44. The stock’s market cap is $822.54 million. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $17.50.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.09. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 101.98% and a negative net margin of 1,323.99%. During the same quarter in the previous year, the business earned ($0.75) earnings per share. On average, equities analysts predict that Dynavax Technologies Corporation will post ($1.72) earnings per share for the current year.

DVAX has been the subject of several analyst reports. Zacks Investment Research upgraded Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Monday, July 10th. Royal Bank Of Canada set a $7.00 price target on Dynavax Technologies Corporation and gave the stock a “hold” rating in a research report on Wednesday, July 26th. BidaskClub downgraded Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday. Cowen and Company restated an “outperform” rating and issued a $45.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Dynavax Technologies Corporation presently has a consensus rating of “Hold” and a consensus price target of $23.67.

WARNING: “Dynavax Technologies Corporation (NASDAQ:DVAX) Receiving Very Favorable Press Coverage, Accern Reports” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Insider Buying and Selling by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.